DEC. 8-14, 2023
Eli Lilly and Co. has struck pharmaceutical gold with its obesity drug, Zepbound. But the new drug carries a hefty price of $1,060 per month, and insurers and health care plans are balking, questioning its affordability. John Russell explores the ramifications for patients and the health-care cost debate. Also in this issue, Susan Orr reports the banking industry foresees an end to the slump in financial stocks. And Mickey Shuey explains how Indy-area logistics companies are using drones to help them track inventory inside giant warehouses.